Document is current
Any future updates will be listed below
-
Authors
Sango, Junya https://orcid.org/0009-0001-8763-4270
Carcamo, Saul https://orcid.org/0000-0002-1510-1045
Sirenko, Maria https://orcid.org/0000-0001-7816-8071
Maiti, Abhishek
Mansour, Hager
Ulukaya, Gulay
Tomalin, Lewis E. https://orcid.org/0000-0003-4545-7138
Cruz-Rodriguez, Nataly
Wang, Tiansu
Olszewska, Malgorzata
Olivier, Emmanuel https://orcid.org/0000-0001-9288-1746
Jaud, Manon
Nadorp, Bettina https://orcid.org/0000-0003-1974-8425
Kroger, Benjamin https://orcid.org/0000-0001-5675-9102
Hu, Feng https://orcid.org/0000-0001-9605-7594
Silverman, Lewis
Chung, Stephen S.
Wagenblast, Elvin https://orcid.org/0000-0002-0709-2759
Chaligne, Ronan https://orcid.org/0000-0003-4332-3291
Eisfeld, Ann-Kathrin https://orcid.org/0000-0001-6442-1419
Demircioglu, Deniz https://orcid.org/0000-0001-7857-0407
Landau, Dan A.
Lito, Piro https://orcid.org/0000-0003-2196-3503
Papaemmanuil, Elli https://orcid.org/0000-0003-1709-8983
DiNardo, Courtney D. https://orcid.org/0000-0001-9003-0390
Hasson, Dan
Konopleva, Marina https://orcid.org/0000-0002-9347-2212
Papapetrou, Eirini P. https://orcid.org/0000-0001-7002-417X
- License Information
-
More Information
Article History
Received: 26 July 2023
Accepted: 30 September 2024
First Online: 30 October 2024
Competing interests
: M.K. receives research support from Klondike, AbbVie and Janssen, and consulting fees from AbbVie, Syndax, Novartis, Servier, AbbVie, Menarini-Stemline Therapeutics, Adaptive, Dark Blue Therapeutics, MEI Pharma, Legend Biotech, Sanofi Aventis, Auxenion GmbH, Vincerx, Curis, Intellisphere and Janssen. D.A.L. is an advisory board member of Mission Bio, Veracyte, Pangea and Alethiomics and has received research support from Ultima Genomics unrelated to this work. A.M. receives research support from Chimeric Therapeutics, Lin Biosciences, Hibercell Inc., Qurient and Molecular Templates, Inc. C.D.D. has received consulting fees from Abbvie, AstraZeneca, Astellas, GenMab, Notable Labs, Rigel and Servier. E.P. is cofounder of, and holds a fiduciary role in Isabl Inc. P.L. has received grants to his Institution from Amgen, Mirati, Revolution Medicines, Boehringer Ingelheim and Virtec Pharmaceuticals. P.L. is an advisory board member of Frontier Medicines, Ikena, Biotheryx and PAQ-Tx (consulting fees and equity in each) and has received consulting fees or honoraria from Black Diamond Therapeutics, AmMax, OrbiMed, PAQ-Tx, Repare Therapeutics, Boehringer Ingelheim and Revolution Medicines. EPP has received consulting fees or honoraria from Janssen, Daiichi Sankyo and Cellarity, unrelated to the current study. The other authors declare no competing interests.
